Early R-CHOP therapy assessment using FLT PET/CT in patients with DLBCL treated with R-CHOP - the initial results

被引：0
|
作者：
Malkowski, B. [1 ]
Chmielowska, E. [1 ]
Olejnik, M. [1 ]
Pietrzak, T. [1 ]
Makarewicz, A. [1 ]
Kachniarz, A. [1 ]
Kasprzak, K. [1 ]
机构：
[1] Ctr Oncol, Bydgoszcz, Poland
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2011年 / 38卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
引用
收藏
页码：S250 / S251
页数：2
相关论文
共 50 条
  • [41] Beta-2 microglobulin is a strong prognostic factor in patients with DLBCL receiving R-CHOP therapy
    Miyashita, Kazuho
    Tomita, Naoto
    Taguri, Masataka
    Suzuki, Taisei
    Ishiyama, Yasufumi
    Ishii, Yoshimi
    Nakajima, Yuki
    Numata, Ayumi
    Hattori, Yukako
    Yamamoto, Wataru
    Miyazaki, Takuya
    Tachibana, Takayoshi
    Takasaki, Hirotaka
    Matsumoto, Kenji
    Hashimoto, Chizuko
    Takemura, Sachiya
    Yamazaki, Etsuko
    Fujimaki, Katsumichi
    Sakai, Rika
    Motomura, Shigeki
    Ishigatsubo, Yoshiaki
    LEUKEMIA RESEARCH, 2015, 39 (11) : 1187 - 1191
  • [42] Factors Relating to the Favorable Outcome in Reduced-Dose R-CHOP Therapy for Elderly DLBCL Patients
    Ono, Keiko
    Tsujimura, Hideki
    Maruyama, Satoshi
    Satou, Akiyasu
    Sugawara, Takeaki
    Kumagai, Kyoya
    BLOOD, 2018, 132
  • [43] The Impact of Trial Eligibility Criteria on Outcomes in a Nationwide Cohort of Newly Diagnosed DLBCL Patients Treated with R-CHOP
    Severinsen, Freja Tang
    Hanstrup, Laura Mors
    Jensen, Rasmus Kuhr
    Maurer, Matthew J.
    Khurana, Arushi
    Jensen, Paw
    Jorgensen, Judit
    Larsen, Thomas Stauffer
    Clausen, Michael Roost
    Poulsen, Christian Bjorn
    Brown, Peter de Nully
    El-Galaly, Tarec Christoffer
    Jakobsen, Lasse H.
    BLOOD, 2021, 138
  • [44] Predictive value of initial 18FLT-uptake in patients with diffuse large B cell lymphoma (DLBCL) undergoing R-CHOP treatment
    Herrmann, Ken
    Dechow, Tobias
    Wieder, Hinrich
    Juenger, Alexandra
    Ringshausen, Ingo
    Keller, Ulrich
    Schuster, Tibor
    Wester, Hans-Juergen
    Schwaiger, Markus
    Buck, Andreas
    JOURNAL OF NUCLEAR MEDICINE, 2010, 51
  • [45] Characterising Tumour and Microenvironmental Responses to R-CHOP in Immunocompetent Mouse Models of DLBCL
    Maybury, Bernard D.
    Bewicke-Copley, Findlay
    Peter, Johnson
    Fitzgibbon, Jude
    Calado, Dinis Pedro
    BLOOD, 2021, 138
  • [46] Limited role of interim PET/CT in patients with diffuse large B-cell lymphoma treated with R-CHOP
    Changhoon Yoo
    Dae Ho Lee
    Jeong Eun Kim
    Jungmin Jo
    Dok Hyun Yoon
    Byeong Seok Sohn
    Sang-We Kim
    Jung-Shin Lee
    Cheolwon Suh
    Annals of Hematology, 2011, 90 : 797 - 802
  • [47] R-GCVP As Second Line Treatment in Elderly Patients with DLBCL Who Fail R-CHOP and Are Not Candidates for Intensive Therapy
    Gration, B.
    Duran, A.
    Mir, N.
    Yuen, L.
    Warner, M.
    Stanley, K.
    Brady, J.
    Mikhaeel, G.
    Fields, P.
    Wrench, D.
    BRITISH JOURNAL OF HAEMATOLOGY, 2018, 181 : 172 - 172
  • [48] Limited role of interim PET/CT in patients with diffuse large B-cell lymphoma treated with R-CHOP
    Yoo, Changhoon
    Lee, Dae Ho
    Kim, Jeong Eun
    Jo, Jungmin
    Yoon, Dok Hyun
    Sohn, Byeong Seok
    Kim, Sang-We
    Lee, Jung-Shin
    Suh, Cheolwon
    ANNALS OF HEMATOLOGY, 2011, 90 (07) : 797 - 802
  • [49] Phase III Trial of Subcutaneous Epcoritamab plus R-CHOP Versus R-CHOP Alone in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL): EPCORE DLBCL-2
    Sehn, Laurie
    Chamuleau, Martine
    Lenz, Georg
    Clausen, Michael
    Haioun, Corinne
    Izutsu, Koji
    Davies, Andrew
    Zhu, Jun
    Oki, Toshiko
    Szafer-Glusman, Edith
    Conlon, Rebekah
    Chiou, Hueiyu
    Ipe, David
    Elliott, Brian
    Wu, Jun
    Salles, Gilles
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S440 - S440
  • [50] Has R-CHOP Really Been Replaced as Initial Therapy of Diffuse Large B-cell Lymphoma (DLBCL)?
    Friedberg, Jonathan W.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S89 - S90
12345